GCT has started First-in-Human clinical study of the new drug based on double recombinant vaccine virus VV-GMCSF-Lact. The study is gained to the evaluation of the safety, tolerability and pharmacokinetic parameters of the investigational product in patients with recurrent/refractory metastatic breast cancer.
In preclinical studies the drug inhibited the development of a number of solid tumors and the index of the breast tumors growth inhibition exceeded 80%. GCT is proud to be the part of the development of the new innovative anticancer therapy.
The study is fully managed by GCT and is conducted in close cooperation with leading medical professionals. The regulatory approval has already been obtained; first patients have been enrolled and have already been treated by the initial dose of the investigational product.
“GCT is proud to achieve this milestone in a short period of time. We are able to reliably support such a significant project, working in accordance with international quality standards. GCT is thrilled to enhance our cancer trials portfolio and to build strong partnership with our new client,“ – said Dr. Eugene Selivra, GCT CEO.
Contact us at bd@gctrials.com to find out more and discuss your project.